Expression Profile of Relapsed/Refractory Aggressive B-cell Non Hodgkin Lymphoma Tumors

Fimepinostat (formerly known as CUDC-907) is a synthetic, orally-available, small molecule that potently inhibits the activity of histone deacetylase, or HDAC, and phosphotidyl-inositol 3 kinase, or PI3 kinase enzymes. Subjects were aggregated from Phase I and II clinical trials (ClinicalTrials.gov Identifier: NCT01742988, NCT02674750) to evaluate efficacy and safety in Lymphoma(s). RNA Seq expression profiles were developed from 34 samples from trial subjects with FFPE tissue samples available and who had been on treatment for at least 42 days. Overall design: 34 FFPE tissue samples from relapsed-refractory diffuse large B-cell lymphoma (RR DLBCL) patients treated with Fimepinostat for at least 42 days were analyzed. DNA and RNA were isolated and assayed for concentration by fluorescence assay. Extracted RNA quality was assayed by Agilent Bioanalyzer 28S/18S (0.8 – 3.0) or Agilent Bioanalyzer RIN score >= 6.0. Hi quality RNA Samples were processed by Illumina TruSeq RNA Exome library preparation for RNA Seq profiling (Illumina). For each sample, 20 – 30 million 50 bp paired end reads were sequenced on Illumina HiSeq2500 platform. RNA Seq reads were mapped to the Homo sapiens reference human_g1k_v37_decoy genome via STAR/GATK workflow and the Gencode v19 annotation.